NeuroCores, Inc.
Pre-clinical biotechnology company developing synthetic plasmalogen derivatives as therapeutics for rare pediatric neurological disorders (e.g., Rett syndrome, Leigh syndrome) and neurodegenerative diseases. Activities described on the site include medicinal chemistry of plasmalogen derivatives, preclinical in vivo efficacy and safety studies, analytical methods for plasmalogen detection, regulatory engagement for orphan/rare pediatric designations, and collaborations with academic research groups.
Industries
N/A
Nr. of Employees
small (1-50)
NeuroCores, Inc.
Products
KIT-13
A synthetic plasmalogen derivative developed as an orally administered small molecule intended to increase brain plasmalogen levels, reduce neuroinflammation, restore mitochondrial function, promote neurogenesis, and improve neuronal survival and function.
KIT-13
A synthetic plasmalogen derivative developed as an orally administered small molecule intended to increase brain plasmalogen levels, reduce neuroinflammation, restore mitochondrial function, promote neurogenesis, and improve neuronal survival and function.
Services
Collaborative R&D engagement model to work with academic institutions and external partners on plasmalogen research and therapeutic development.
Collaborative R&D engagement model to work with academic institutions and external partners on plasmalogen research and therapeutic development.
Expertise Areas
- Plasmalogen derivative therapeutics
- Preclinical and IND‑enabling development
- Neuroinflammation and neurodegeneration biology
- Medicinal chemistry and small-molecule design
Key Technologies
- Synthetic plasmalogen chemistry
- Oral small‑molecule therapeutic design
- Blood–brain barrier penetration optimization
- Animal disease models (Rett syndrome, Leigh syndrome, Alzheimer’s models)
News & Updates
NeuroCores incorporated in April 2023 as a U.S. subsidiary of the Institute of Rheological Functions of Food (Fukuoka, Japan); company based in Boston, Massachusetts.
IND submission for the lead asset planned in 2025 with initiation of a Phase I clinical study scheduled thereafter.
Summary of studies describing plasmalogen roles in preventing neuroinflammation, improving cognitive function, and inhibiting neuronal cell death.
Research describing how plasmalogens protect neuronal cells from apoptosis via activation of survival signaling pathways.
Study reporting that plasmalogens increase expression of BDNF in the hippocampus and promote neurogenesis associated with improved learning and memory in mice.
Lead asset granted Rare Pediatric Disease Designation for Rett syndrome by the US FDA.
NeuroCores incorporated in April 2023 as a U.S. subsidiary of the Institute of Rheological Functions of Food (Fukuoka, Japan); company based in Boston, Massachusetts.
IND submission for the lead asset planned in 2025 with initiation of a Phase I clinical study scheduled thereafter.
Summary of studies describing plasmalogen roles in preventing neuroinflammation, improving cognitive function, and inhibiting neuronal cell death.
Research describing how plasmalogens protect neuronal cells from apoptosis via activation of survival signaling pathways.
Study reporting that plasmalogens increase expression of BDNF in the hippocampus and promote neurogenesis associated with improved learning and memory in mice.
Lead asset granted Rare Pediatric Disease Designation for Rett syndrome by the US FDA.